In both types of tissue, increased expression of claudin-3 was seen in the majority of cases examined, and was seen more frequently than in non-neoplastic tissue, indicating that it may serve as an important biomarker for prostate cancer. This evidence concerns the gene CLDN3 and prostate carcinoma.